Detalles de la búsqueda
1.
Recurrent disability progression endpoints in multiple sclerosis clinical trials.
Mult Scler;
29(1): 130-139, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36177953
2.
Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials.
Eur J Neurol;
29(4): 1238-1242, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33724637
3.
ENSEMBLE PLUS: final results of shorter ocrelizumab infusion from a randomized controlled trial.
J Neurol;
2024 Apr 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-38649522
4.
Estimating drug concentration-response relationships by applying causal inference methods for continuous point exposures and time-to-event outcomes.
Stat Methods Med Res;
32(12): 2440-2454, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37964549
5.
Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis.
Neurol Neuroimmunol Neuroinflamm;
10(2)2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36792367
6.
Results of a phase I trial to assess the safety of macitentan in combination with temozolomide for the treatment of recurrent glioblastoma.
Neurooncol Adv;
3(1): vdab141, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34693288
7.
Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study.
Neurology;
95(14): e1999-e2008, 2020 10 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32727835
8.
Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
Lancet Neurol;
19(12): 998-1009, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33129442
9.
Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials.
JAMA Neurol;
77(9): 1132-1140, 2020 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32511687
10.
Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension.
Neurology;
95(13): e1854-e1867, 2020 09 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-32690791
Resultados
1 -
10
de 10
1
Próxima >
>>